A Phase II Study of the Efficacy and Tolerability of the Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 02 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 06 Oct 2011 Planned End Date changed from 1 Sep 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.